147 related articles for article (PubMed ID: 16039673)
1. Computational modeling of the immune response to tumor antigens.
Castiglione F; Toschi F; Bernaschi M; Succi S; Benedetti R; Falini B; Liso A
J Theor Biol; 2005 Dec; 237(4):390-400. PubMed ID: 16039673
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic cancer vaccines.
Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
[TBL] [Abstract][Full Text] [Related]
3. New possibilities for cancer therapy with advances in cancer immunology.
MacLean GD; Longenecker BM
Can J Oncol; 1994 Apr; 4(2):249-54. PubMed ID: 7516257
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy, mathematical modeling and optimal control.
Castiglione F; Piccoli B
J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
[TBL] [Abstract][Full Text] [Related]
5. Vaccine therapy for cancer: fact or fiction?
Odunsi K; Lele S; Savalgi R
Surg Technol Int; 2004; 13():39-47. PubMed ID: 15744673
[TBL] [Abstract][Full Text] [Related]
6. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
Sensi M; Anichini A
Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of MVA-based therapeutic cancer vaccines.
Acres B; Bonnefoy JY
Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
[TBL] [Abstract][Full Text] [Related]
8. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
9. Boosting the immune response: an alternative combination therapy for cancer patients.
Thyphronitis G; Koutsilieris M
Anticancer Res; 2004; 24(4):2443-53. PubMed ID: 15330197
[TBL] [Abstract][Full Text] [Related]
10. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
11. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
13. MMP11: a novel target antigen for cancer immunotherapy.
Peruzzi D; Mori F; Conforti A; Lazzaro D; De Rinaldis E; Ciliberto G; La Monica N; Aurisicchio L
Clin Cancer Res; 2009 Jun; 15(12):4104-13. PubMed ID: 19509157
[TBL] [Abstract][Full Text] [Related]
14. Processing and presentation of tumor antigens and vaccination strategies.
van der Bruggen P; Van den Eynde BJ
Curr Opin Immunol; 2006 Feb; 18(1):98-104. PubMed ID: 16343880
[TBL] [Abstract][Full Text] [Related]
15. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
17. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Jinushi M; Hodi FS; Dranoff G
Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
[TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines: a promising cancer therapy against all odds.
Silk AW; Finn OJ
Future Oncol; 2007 Jun; 3(3):299-306. PubMed ID: 17547525
[TBL] [Abstract][Full Text] [Related]
20. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.
Singh R; Paterson Y
Expert Rev Vaccines; 2006 Aug; 5(4):541-52. PubMed ID: 16989634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
